Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
2024; Elsevier BV; Volume: 190; Linguagem: Inglês
10.1016/j.ygyno.2024.07.024
ISSN1095-6859
AutoresPanagiotis A. Konstantinopoulos, Jae‐Weon Kim, Gilles Freyer, Jung-Yun Lee, Lydia Gaba, Rachel N. Grisham, N. Colombo, Xiaohua Wu, Jalid Sehouli, Felipe Melo Cruz, David Cibula, Bradley J. Monk, Gitte‐Bettina Nyvang, Michael Friedlander, Domenica Lorusso, Els Van Nieuwenhuysen, Rosalind Glasspool, Christian Marth, Patsy Hinson, Monica Zuradelli, Craig Wang, Faye Su, Michelle Miller, Ursula A. Matulonis, Antonio González‐Martín,
Tópico(s)BRCA gene mutations in cancer
Referência(s)